166 related articles for article (PubMed ID: 12358513)
1. Development of a potent Bcl-x(L) antagonist based on alpha-helix mimicry.
Kutzki O; Park HS; Ernst JT; Orner BP; Yin H; Hamilton AD
J Am Chem Soc; 2002 Oct; 124(40):11838-9. PubMed ID: 12358513
[TBL] [Abstract][Full Text] [Related]
2. Terphenyl-Based Bak BH3 alpha-helical proteomimetics as low-molecular-weight antagonists of Bcl-xL.
Yin H; Lee GI; Sedey KA; Kutzki O; Park HS; Orner BP; Ernst JT; Wang HG; Sebti SM; Hamilton AD
J Am Chem Soc; 2005 Jul; 127(29):10191-6. PubMed ID: 16028929
[TBL] [Abstract][Full Text] [Related]
3. Terephthalamide derivatives as mimetics of the helical region of Bak peptide target Bcl-xL protein.
Yin H; Hamilton AD
Bioorg Med Chem Lett; 2004 Mar; 14(6):1375-9. PubMed ID: 15006365
[TBL] [Abstract][Full Text] [Related]
4. Design and application of an alpha-helix-mimetic scaffold based on an oligoamide-foldamer strategy: antagonism of the Bak BH3/Bcl-xL complex.
Ernst JT; Becerril J; Park HS; Yin H; Hamilton AD
Angew Chem Int Ed Engl; 2003 Feb; 42(5):535-9. PubMed ID: 12569483
[No Abstract] [Full Text] [Related]
5. Terephthalamide derivatives as mimetics of helical peptides: disruption of the Bcl-x(L)/Bak interaction.
Yin H; Lee GI; Sedey KA; Rodriguez JM; Wang HG; Sebti SM; Hamilton AD
J Am Chem Soc; 2005 Apr; 127(15):5463-8. PubMed ID: 15826183
[TBL] [Abstract][Full Text] [Related]
6. Anti-apoptotic Bcl-XL protein in complex with BH3 peptides of pro-apoptotic Bak, Bad, and Bim proteins: comparative molecular dynamics simulations.
Lama D; Sankararamakrishnan R
Proteins; 2008 Nov; 73(2):492-514. PubMed ID: 18452209
[TBL] [Abstract][Full Text] [Related]
7. Structure of Bcl-xL-Bak peptide complex: recognition between regulators of apoptosis.
Sattler M; Liang H; Nettesheim D; Meadows RP; Harlan JE; Eberstadt M; Yoon HS; Shuker SB; Chang BS; Minn AJ; Thompson CB; Fesik SW
Science; 1997 Feb; 275(5302):983-6. PubMed ID: 9020082
[TBL] [Abstract][Full Text] [Related]
8. Structural biology of the Bcl-2 family of proteins.
Petros AM; Olejniczak ET; Fesik SW
Biochim Biophys Acta; 2004 Mar; 1644(2-3):83-94. PubMed ID: 14996493
[TBL] [Abstract][Full Text] [Related]
9. Identification of small-molecule inhibitors of interaction between the BH3 domain and Bcl-xL.
Degterev A; Lugovskoy A; Cardone M; Mulley B; Wagner G; Mitchison T; Yuan J
Nat Cell Biol; 2001 Feb; 3(2):173-82. PubMed ID: 11175750
[TBL] [Abstract][Full Text] [Related]
10. Rationale for Bcl-xL/Bad peptide complex formation from structure, mutagenesis, and biophysical studies.
Petros AM; Nettesheim DG; Wang Y; Olejniczak ET; Meadows RP; Mack J; Swift K; Matayoshi ED; Zhang H; Thompson CB; Fesik SW
Protein Sci; 2000 Dec; 9(12):2528-34. PubMed ID: 11206074
[TBL] [Abstract][Full Text] [Related]
11. Structure and function of benzoylurea-derived alpha-helix mimetics targeting the Bcl-x(L)/Bak binding interface.
Rodriguez JM; Ross NT; Katt WP; Dhar D; Lee GI; Hamilton AD
ChemMedChem; 2009 Apr; 4(4):649-56. PubMed ID: 19330783
[TBL] [Abstract][Full Text] [Related]
12. (alpha/beta+alpha)-peptide antagonists of BH3 domain/Bcl-x(L) recognition: toward general strategies for foldamer-based inhibition of protein-protein interactions.
Sadowsky JD; Fairlie WD; Hadley EB; Lee HS; Umezawa N; Nikolovska-Coleska Z; Wang S; Huang DC; Tomita Y; Gellman SH
J Am Chem Soc; 2007 Jan; 129(1):139-54. PubMed ID: 17199293
[TBL] [Abstract][Full Text] [Related]
13. alpha-Helix mimetics as inhibitors of protein-protein interactions.
Saraogi I; Hamilton AD
Biochem Soc Trans; 2008 Dec; 36(Pt 6):1414-7. PubMed ID: 19021566
[TBL] [Abstract][Full Text] [Related]
14. Relationship between helix stability and binding affinities: molecular dynamics simulations of Bfl-1/A1-binding pro-apoptotic BH3 peptide helices in explicit solvent.
Modi V; Lama D; Sankararamakrishnan R
J Biomol Struct Dyn; 2013; 31(1):65-77. PubMed ID: 22803956
[TBL] [Abstract][Full Text] [Related]
15. Structure-activity relationships of Bak derived peptides: affinity and specificity modulations by amino acid replacement.
Frey V; Viaud J; Subra G; Cauquil N; Guichou JF; Casara P; Grassy G; Chavanieu A
Eur J Med Chem; 2008 May; 43(5):966-72. PubMed ID: 17692431
[TBL] [Abstract][Full Text] [Related]
16. Design and modular parallel synthesis of a MCR derived alpha-helix mimetic protein-protein interaction inhibitor scaffold.
Antuch W; Menon S; Chen QZ; Lu Y; Sakamuri S; Beck B; Schauer-Vukasinović V; Agarwal S; Hess S; Dömling A
Bioorg Med Chem Lett; 2006 Mar; 16(6):1740-3. PubMed ID: 16427279
[TBL] [Abstract][Full Text] [Related]
17. Nuclear magnetic resonance study of protein-protein interactions involving apoptosis regulator Diva (Boo) and the BH3 domain of proapoptotic Bcl-2 members.
Santiveri CM; Sborgi L; de Alba E
J Mol Recognit; 2012 Dec; 25(12):665-73. PubMed ID: 23192964
[TBL] [Abstract][Full Text] [Related]
18. A comparison of two strategies for affinity maturation of a BH3 peptide toward pro-survival Bcl-2 proteins.
Zhang S; Long A; Link AJ
ACS Synth Biol; 2012 Mar; 1(3):89-98. PubMed ID: 23651073
[TBL] [Abstract][Full Text] [Related]
19. Solution structure of human BCL-w: modulation of ligand binding by the C-terminal helix.
Denisov AY; Madiraju MS; Chen G; Khadir A; Beauparlant P; Attardo G; Shore GC; Gehring K
J Biol Chem; 2003 Jun; 278(23):21124-8. PubMed ID: 12651847
[TBL] [Abstract][Full Text] [Related]
20. Structural basis for the conserved binding mechanism of MDM2-inhibiting peptides and anti-apoptotic Bcl-2 family proteins.
Lee MS; Ha JH; Yoon HS; Lee CK; Chi SW
Biochem Biophys Res Commun; 2014 Feb; 445(1):120-5. PubMed ID: 24491548
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
